ACTA1-Related Nemaline Myopathy: Comprehensive Research Report

Identifiers

• Gene: ACTA1 (actin alpha 1, skeletal muscle) — HGNC:129, NCBI Gene ID: 58, chromosome 1q42.13 (Atlas Genet Cytogenet Oncol Haematol; PMID:10072583)
• OMIM gene: 102610 — ACTIN, ALPHA-1, SKELETAL MUSCLE; ACTA1 (omim.org/entry/102610)
• OMIM phenotypes (phenotypic series, current nosology):
• #161800 — Congenital myopathy 2A, typical, autosomal dominant (CMYO2A; historically "Nemaline myopathy 3," NEM3)
• #620265 — Congenital myopathy 2B, severe infantile, autosomal recessive (CMYO2B)
• #620278 — Congenital myopathy 2C, severe infantile, autosomal dominant (CMYO2C)
• Additional allelic entities discussed below: actin-accumulation myopathy, intranuclear rod myopathy, cap myopathy, congenital fiber-type disproportion (CFTD), and an emerging dilated-cardiomyopathy/distal-myopathy spectrum
• MONDO: MONDO:0008070; MedGen: C3711389
• UniProt: P68133 (skeletal muscle α-actin, ACTS_HUMAN); MGI (mouse ortholog): MGI:87902 (Acta1)
• Orphanet lists nemaline myopathy generically with ACTA1 as a causal gene; I was not able to retrieve a confirmed disease-specific ORPHA code for the ACTA1 subtype from the sources fetched in this session — flagged as a gap rather than guessed.

Most of what follows is aggregated disease-level knowledge (literature cohorts, structured databases, model-organism studies) rather than a single-patient EHR source.

1. Disease Overview

Nemaline myopathy (NM) is a clinically and genetically heterogeneous group of congenital skeletal-muscle disorders defined by the presence of rod-like ("nemaline") inclusions in myofibers on biopsy, together with hypotonia and weakness of variable severity. ACTA1, encoding skeletal muscle α-actin — the core building block of the sarcomeric thin filament — is the second most common causal gene after NEB (nebulin) for NM overall, but the single most common cause of the severe subset: "ACTA1 accounts for more than half of the severe NM cases" (PMC9271256; Acta Neuropathol Commun 2022, doi:10.1186/s40478-022-01400-0). Population-level estimates place ACTA1 at roughly 20–41% of genetically solved NM cohorts depending on severity mix, and ACTA1 variants overall account for ~15–25% of all congenital myopathy diagnoses (search synthesis of multiple reviews; PMID:22825594 Nowak, Ravenscroft & Laing, Acta Neuropathol 2013).

Common synonyms/related terms: nemaline myopathy 3 (NEM3, legacy name), actin-accumulation myopathy, congenital myopathy with excess of thin filaments, intranuclear rod myopathy, cap myopathy (specific to the p.Met47Val variant), and — increasingly recognized as distinct, non-NM phenotypes from the same gene — congenital fiber-type disproportion (CFTD), ACTA1-related dilated cardiomyopathy, and an emerging ACTA1-related distal myopathy.

2. Etiology

Disease causal factor. ACTA1-related myopathy is a purely monogenic structural-protein disorder — no environmental, infectious, or multifactorial contribution to primary causation has been established. All causation is genetic, arising through two distinct molecular routes (detailed in §4/§6):

• Dominant, usually de novo, missense mutation — a mutant actin monomer is incorporated into the thin filament alongside wild-type actin, producing a dominant-negative/poison-subunit effect rather than haploinsufficiency. This explains 93.3% (365/391) of pathogenic/likely-pathogenic (P/LP) ACTA1 variants in the most recent curated update, of which 88% are confirmed de novo (PMC11918651, Clayton et al., Hum Mutat 2024/2025 variant-database update).
• Biallelic (homozygous/compound-heterozygous) loss-of-function (frameshift/nonsense) — complete absence of skeletal α-actin protein, accounting for 6.6% (26/391) of P/LP variants, and producing severe, often lethal disease (PMID:25182138, Eur J Hum Genet 2015, "Recessive ACTA1 variant causes congenital muscular dystrophy with rigid spine").

Genetic risk factors. The gene itself is the risk factor; there is no described common susceptibility-locus or polygenic contribution. gnomAD constraint data are informative for interpreting variant pathogenicity: ACTA1 is markedly missense-constrained (only ~21% of expected missense variants observed genome-wide-length-adjusted; ranked 164th of 19,704 genes for missense intolerance) but tolerant of loss-of-function heterozygosity (pLI 0; o/e 0.74, 11 observed/14.9 expected) — consistent with the mechanism above: a null allele is silent in the heterozygous state, and disease from LoF variants requires biallelic loss (PMC11918651).

Environmental risk factors: none identified.

Protective factors. A partial biological "rescue" mechanism has been demonstrated in the recessive-null state: cardiac (fetal) α-actin (ACTC1) is normally co-expressed in developing skeletal muscle and down-regulated postnatally; in Acta1-null mice, sustained/elevated ACTC1 expression is sufficient to functionally substitute for absent skeletal α-actin and rescue lethality — "ACTC is sufficiently similar to ACTA1 to produce adequate function in postnatal skeletal muscle" (PMID:19468071, Nowak et al., J Cell Biol 2009). This is the leading candidate explanation for why some biallelic-null human patients survive rather than uniformly dying perinatally, and it has been explicitly pursued as a therapeutic strategy for dominant ACTA1 disease as well (cardiac α-actin over-expression therapy; PMID:23736297) — see §12.

Gene-environment interactions: none reported; this is not a gene-environment-interaction disease model.

3. Phenotypes

Phenotype data below are drawn from aggregated multi-patient literature cohorts (case-series/systematic reviews), not from a single registry with formal frequency validation — treat percentages as literature-derived estimates from the specific cohorts cited, which differ in inclusion criteria (severity-enriched vs. unselected).

Core/near-universal features | Phenotype | Onset/pattern | Frequency (source cohort) | Suggested HPO | |---|---|---|---| | Neonatal hypotonia | Congenital | Near-universal in congenital forms | HP:0001319 | | Generalized muscle weakness, neck-flexor and respiratory predominance | Congenital–childhood | Defining feature of "typical" form | HP:0003324 | | Respiratory insufficiency/failure | Neonatal–progressive | 75/143 significant first-year respiratory disease (PMID:11558787, Ryan et al., Ann Neurol 2001); dyspnea in 55% of a pediatric cohort (n=101) | HP:0002093 / HP:0004879 | | Feeding difficulty/dysphagia | Neonatal onward | 79/143 (Ryan et al.); 47% dysphagia in pediatric cohort | HP:0002015 / HP:0011968 | | Hypo-/areflexia | Congenital | Common | HP:0001265 | | Axial (truncal) weakness | Variable | 68% (pediatric systematic review, n=101, PMC10032635) | HP:0003701 |

Musculoskeletal/structural - Arthrogryposis multiplex congenita (HP:0002804) — a strong early-mortality predictor - High-arched palate (HP:0002705), facial weakness/myopathic facies - Kyphoscoliosis/scoliosis (HP:0002650) — a major progressive complication in survivors - Pectus excavatum (HP:0000767), clubfoot/pes planus (HP:0001762) - Fractures, joint contractures, skull enlargement (pediatric systematic review, PMC10032635)

Atypical/emerging phenotypes (from the largest recent cohort, n=275): ophthalmoplegia, unusual weakness distribution, cardiomyopathy, and intranuclear rods as "atypical" ACTA1 presentations (PMID:40661861, Neurol Genet 2025).

Prenatal (severe end of spectrum) - Fetal akinesia/reduced fetal movement (HP:0001989), polyhydramnios (HP:0001561, from impaired fetal swallowing, appearing from ~28 weeks), intrauterine growth restriction, pulmonary hypoplasia — the fetal akinesia deformation sequence (FADS), of which ACTA1 is a recognized cause via de novo or somatic mosaic variants (search synthesis; general FADS population incidence ~1:15,000 in a Danish study, not ACTA1-specific).

Laboratory - Creatine kinase typically normal to mildly elevated (reported means ~107 IU/L, range 25–369) — a distinguishing feature from dystrophic myopathies (search synthesis of case reports).

Quality of life. No ACTA1-specific EQ-5D/SF-36 data were located; qualitatively, respiratory failure, feeding dependence, and progressive scoliosis are the dominant drivers of morbidity and caregiver burden, and these tend to diminish with age in survivors while chronic weakness and orthopedic sequelae persist (PMID:11558787).

4. Genetic/Molecular Information

Variant landscape (most current source: Clayton et al. curated update, PMC11918651): - 607 total reported variants across HGMD/LOVD/ClinVar; after ACMG/AMP reclassification, 447 pathogenic/likely pathogenic, 13 VUS, 147 benign/likely benign. - Type distribution among 391 analyzed P/LP variants: missense 340 (87.0%), frameshift 18 (4.6%), nonsense 13 (3.3%), splicing 9 (2.3%), in-frame indel 6 (1.5%), stop-loss 3 (0.8%), start-loss 2 (0.5%). - Inheritance: dominant 365/391 (93.3%) (88% of these confirmed de novo), recessive 26/391 (6.6%). - Missense P/LP variants affect 154/377 (40.8%) of ACTA1 residues; across all six human actin isoforms, disease-associated missense variants collectively involve 345/377 (91.5%) residues — reflecting near-total intolerance of the actin fold to substitution. - Phenotype distribution among P/LP variants: nemaline myopathy 74%, congenital fiber-type disproportion 7.2%, intranuclear rod myopathy 4.3%, cardiomyopathies 5.3% (dilated most common), fetal abnormalities 5.3%, and an emerging distal myopathy phenotype (4 reported families) — 20 distinct clinical presentations recorded in total.

Structural mechanism. Skeletal α-actin folds into two lobes each with two subdomains (SD1–SD4); a cleft between SD2 and SD4 binds ATP/ADP·Mg²⁺, clamped by phosphate-binding loops P1 (residues 11–16) and P2 (residues 154–161), while a separate cleft between SD1 and SD3 mediates binding of most actin-binding proteins, including myosin and tropomyosin (search synthesis of structural biology literature). Disease variants cluster at: - The ATP-binding cleft, disrupting nucleotide binding and polymerization competence; - The actin-actin (longitudinal/lateral filament) interface, impairing thin-filament assembly; - The actin-myosin/tropomyosin interaction surface, directly impairing cross-bridge cycling — demonstrated for p.Asp286Gly, which "prevents proper strong myosin binding and triggers muscle weakness" (PMC3447773, PLOS One).

Dominant-negative evidence. Direct biochemical/cellular evidence for a dominant-negative mechanism (abnormal folding, aggregation, and altered polymerization of mutant actin isoforms) is reported in PMID:15198992. Genotype-phenotype heterogeneity is substantial even for the same or similar residues — "the marked variability in clinical phenotype among patients with different mutations in ACTA1 suggested that both the site of the mutation and the nature of the amino acid change have differential effects on thin-filament formation and protein-protein interactions" (search synthesis; corroborated by PMID:15236405, "Heterogeneity of nemaline myopathy cases with skeletal muscle alpha-actin gene mutations").

Recessive/null mechanism. Biallelic frameshift/nonsense variants abolish ACTA1 protein expression entirely. "Previously reported patients with biallelic ACTA1 mutations had functional 'null' variants and made no ACTA1 protein... All recessive variants reported to date have resulted in loss of skeletal α-actin expression from muscle and severe weakness from birth," with reported deaths at 5 and 19 days of age in the most severe reported cases (search synthesis of case literature; PMID:25182138). Postnatal compensatory upregulation of cardiac (fetal) α-actin (ACTC1) in skeletal muscle is proposed to explain the variable survival seen in some null-recessive patients (mechanistically validated in mice, PMID:19468071).

Cardiomyopathy variants. A distinct, non-skeletal-muscle-predominant phenotype has been reported: p.Arg256His causes dilated cardiomyopathy via disruption of actin structure/function and cardiomyocyte hypocontractility (PMID:38559046, 2024) — evidence that the same gene can produce organ-selective disease depending on variant biochemistry and which sarcomeric isoform environment is affected.

Modifier genes: none formally established for ACTA1 specifically; comparative cohort data show that genotype (ACTA1 vs. NEB) itself modifies early feeding/ventilation needs (§9/§11), but no discrete modifier locus has been identified.

Epigenetic information / chromosomal abnormalities: not applicable/not reported — ACTA1 disease is driven by point mutations and small indels in a single, small (6-exon) protein-coding gene; no epigenetic mechanism or large chromosomal rearrangement has been implicated.

5. Environmental Information

No environmental, lifestyle, or infectious causal factor has been established for ACTA1-related myopathy — it is fully accounted for by the genetic mechanisms above. Infections (particularly respiratory) are a major secondary driver of morbidity and mortality (aspiration, pneumonia) rather than a cause, consistent with the respiratory-muscle weakness and impaired airway clearance intrinsic to the disease (§3, §11).

6. Mechanism / Pathophysiology

Causal chain (numbered, with explicit branch points)

1. A heterozygous, typically de novo, missense mutation in ACTA1 alters the amino-acid sequence of skeletal muscle α-actin at a site critical to the ATP-binding cleft, the actin-actin polymerization interface, or the actin-myosin/tropomyosin binding surface — OR, alternatively, biallelic frameshift/nonsense mutation abolishes ACTA1 protein expression entirely (branch established at step 1; downstream consequences diverge, see step 9).
2. For dominant missense variants: the mutant actin monomer is co-synthesized with wild-type actin and incorporates into growing thin filaments as a "poison subunit" (dominant-negative mechanism), demonstrated directly by abnormal folding, aggregation, and altered polymerization kinetics of mutant actin isoforms (PMID:15198992).
3. This leads to defective actin polymerization — patient-derived fibroblasts show markedly shortened, unstructured actin filaments, with only ~7% of mutant cells achieving correct polymerization versus near-100% of controls (PMC10740811, in vitro, patient fibroblasts).
4. Depending on mutation site, misfolded/mutant actin results in aggregation into rod-like inclusions (classic nemaline/rod bodies, structurally continuous with Z-disks and containing α-actinin, myotilin, and sarcomeric actin), or into intranuclear rods, cytoplasmic bodies, cores, or caps — a branch point in the cascade that determines histopathological subtype rather than clinical severity per se (PMID:22825594; PMC9271256, which additionally reports mislocalization of lamin A/C, Nesprin-1, and Nesprin-2 — nuclear lamina/LINC-complex components — in the severe intranuclear-rod subtype, implicating nuclear envelope dysfunction as a further downstream consequence).
5. Independently of aggregate formation, malformed/incorporated mutant actin impairs sarcomeric cross-bridge cycling: p.Asp286Gly directly prevents proper strong myosin binding, and functional studies confirm that "dysfunctional sarcomere contractility contributes to muscle weakness in ACTA1-related nemaline myopathy" (PMID:29328520).
6. In parallel, actin polymerization failure triggers compensatory RhoA/ROCK1 pathway overactivation (increased active RhoA and phosphorylated ROCK1 in patient fibroblasts) and disrupts actin-dependent regulation of mitochondrial dynamics, leading to mitochondrial network fragmentation (increased DRP1, decreased OPA1), reduced basal/maximal/spare respiration, decreased ATP generation, downregulated OXPHOS complex I–V subunits, and elevated mitochondrial ROS — reproduced independently in ACTA1(H40Y) patient-iPSC-derived skeletal myocytes (PMID:36796746; PMC10740811). This bioenergetic branch is reversible in vitro: 7-day supplementation with linoleic acid and L-carnitine restored actin polymerization and normalized mitochondrial parameters in the fibroblast model.
7. Sarcomeric dysfunction (step 5) plus bioenergetic failure (step 6) jointly reduce contractile force generation, manifesting clinically as generalized hypotonia and weakness, with a predilection for neck-flexor and respiratory muscles.
8. In the most severe prenatal cases, profound failure of fetal muscle contraction causes fetal akinesia/hypokinesia, which in turn produces arthrogryposis multiplex congenita, pulmonary hypoplasia (from lack of fetal breathing movements), and polyhydramnios (from impaired fetal swallowing) — culminating in stillbirth or early neonatal death from respiratory failure in the severest subset.
9. Recessive-null branch: complete absence of ACTA1 protein removes the primary thin-filament structural component entirely; disease severity in this branch is modulated by the degree of postnatal compensatory upregulation of cardiac (fetal) α-actin (ACTC1) in skeletal muscle, which can partially substitute for the missing protein and is sufficient to rescue lethality in Acta1-null mice when sufficiently expressed (PMID:19468071) — this is an inferred mechanism in humans, extrapolated from the mouse rescue experiment rather than directly demonstrated in patient tissue.
10. Postnatally, chronic weakness of paraspinal/postural and respiratory muscles drives a feed-forward cycle: progressive kyphoscoliosis and joint contractures further compromise respiratory mechanics, compounding the primary respiratory-muscle weakness and accounting for most of the long-term morbidity/mortality burden (§11).
11. Divergent-outcome branch: variants affecting the actin-myosin/tropomyosin interface preferentially, without prominent aggregation, instead produce isolated congenital fiber-type disproportion (type 1 fiber hypotrophy without rods) (PMID:17387733, Clarke et al., "The pathogenesis of ACTA1-related congenital fiber type disproportion," Ann Neurol 2007); variants disrupting cardiac-relevant actin-myosin interactions instead cause dilated cardiomyopathy with cardiomyocyte hypocontractility (PMID:38559046); and a small number of families show a distal-predominant weakness pattern — an emerging phenotype not yet mechanistically dissected.

Molecular pathways / GO terms

• Actin filament polymerization (GO:0030041); actomyosin structure organization / sarcomere organization (GO:0045214); striated muscle contraction (GO:0006941); positive regulation of Rho protein signal transduction (GO:0035025, downstream compensatory signaling); mitochondrial fission (GO:0000266) / mitochondrial fusion (GO:0007005); ATP metabolic process (GO:0046034, downstream bioenergetic failure).

Cell types (CL terms)

• Skeletal muscle fiber (CL:0000188); type I (slow) skeletal muscle fiber (CL:0002586, selectively hypotrophic in CFTD); type II (fast) skeletal muscle fiber (CL:0002617); fibroblast (CL:0000057, the in vitro disease model used for the mitochondrial mechanism work); induced pluripotent stem cell-derived skeletal myocyte (used for H40Y iPSC model).

Advanced/omics data

No transcriptomic, proteomic, single-cell, or spatial-transcriptomic dataset specific to ACTA1-related myopathy patient muscle was identified in this search — a data gap relative to better-resourced neuromuscular diseases. The mechanistic omics-adjacent data available is limited to targeted Western blot/qPCR (fibroblast/iPSC studies above) and classical histopathology/electron microscopy; no GEO/ArrayExpress dataset was located for this specific gene-disease pair.

7. Anatomical Structures Affected

Organ level. Primary: skeletal muscle (generalized, with axial/neck-flexor/respiratory predominance in the typical form; distal predominance in the emerging distal phenotype). Secondary: respiratory system (restrictive failure secondary to muscle weakness and scoliosis); cardiac muscle (in the emerging cardiomyopathy phenotype, PMID:38559046); gastrointestinal/oropharyngeal (dysphagia from bulbar/pharyngeal muscle weakness); skeletal system (secondary structural deformity — scoliosis, contractures, pectus excavatum — from chronic weakness rather than a primary skeletal defect).

Tissue/cell level. Skeletal myofibers, particularly type 1 (slow-twitch) fibers in the CFTD phenotype; cardiomyocytes in the cardiomyopathy phenotype.

Subcellular level. Sarcomeric thin filament and Z-disk (GO:0030018, Z disc — the structural origin of nemaline rods); sarcoplasm (site of cytoplasmic bodies/actin aggregates); nucleus and nuclear envelope/lamina (intranuclear rods; mislocalized lamin A/C, Nesprin-1/2 — LINC complex — in the severe subtype, PMC9271256); mitochondria (fragmented network, reduced OXPHOS complex expression).

Localization/laterality. Bilateral, symmetric, generalized muscle involvement is typical; no lateralization is described.

8. Temporal Development

Onset and course (from the landmark 143-patient cohort, PMID:11558787, Ryan et al., Ann Neurol 2001 — the most cited natural-history stratification, applicable to NM broadly and reflected in ACTA1-specific cohorts):

ACTA1-specific data (275-patient cohort, PMID:40661861) show that ACTA1-NM patients are more likely than NEB-NM patients to require feeding tubes and invasive ventilation in the first year of life, though this difference narrows after the first year — consistent with ACTA1 being enriched for the severe end of the clinical spectrum.

Progression pattern. Generally static-to-slowly-progressive in survivors of the congenital forms; a minority develop progressive distal weakness over time. Morbidity from respiratory infections and feeding difficulties characteristically diminishes with age in survivors, while orthopedic complications (scoliosis) tend to worsen during growth/adolescence — a divergent temporal pattern across organ systems.

Critical periods. The neonatal period is the critical window for respiratory/feeding crisis and early mortality; adolescence is the critical window for scoliosis progression and associated respiratory compromise.

9. Inheritance and Population

Epidemiology. Overall nemaline myopathy prevalence is estimated at ~1:50,000 live births worldwide, consistent with a Finnish birth-prevalence estimate of 0.02 per 1,000 live births (search synthesis of multiple reviews). ACTA1 causes an estimated 15–25% of all congenital myopathies and a substantial (cohort-dependent, roughly 20–40%) share of genetically solved NM, rising to >50% of the severe NM subset (PMC9271256).

Inheritance pattern. Autosomal dominant (93.3% of P/LP variants, 88% de novo) or autosomal recessive (6.6%, biallelic null variants) (PMC11918651).

Penetrance/expressivity. Dominant missense disease is essentially fully penetrant but shows marked variable expressivity even for identical or neighboring residue substitutions, attributed to differential effects of mutation site/biochemistry on thin-filament assembly (PMID:15236405).

Germline mosaicism. Not specifically quantified for ACTA1 in the literature retrieved; general empirical recurrence-risk figures for de novo dominant conditions (~1–5%, occasionally much higher with parental gonadal mosaicism) apply generically but are not gene-specific data — a recognized gap. Somatic/germline mosaicism has, however, been specifically implicated as a mechanism for ACTA1-related fetal akinesia in de novo cases (search synthesis).

Founder effects/consanguinity. No founder mutations are described; recessive (biallelic null) cases would be expected to be enriched by consanguinity, consistent with general Mendelian recessive-disease principles, though no ACTA1-specific consanguinity registry data were retrieved.

Sex ratio/geographic distribution. No sex predilection is reported (autosomal gene, both dominant and recessive mechanisms). No geographic clustering or endemic distribution has been described; cases have been reported worldwide (the pediatric systematic review sampled 101 patients from 23 countries, PMC10032635).

10. Diagnostics

Muscle biopsy remains the histopathological gold standard: modified Gömöri trichrome stain reveals red-staining rod/granular sarcoplasmic inclusions (nemaline bodies); electron microscopy confirms sarcoplasmic rods often continuous with Z-disks, and — in the severe ACTA1 subtype specifically — intranuclear rods, cytoplasmic bodies, and enlarged perinuclear space are characteristic distinguishing features from other NM genotypes (PMC9271256). A single biopsy may show multiple co-occurring pathologies (rods, cores, caps, fiber-type disproportion) (PMID:22825594).

Laboratory. Serum creatine kinase is typically normal to only mildly elevated — a useful negative discriminator against dystrophic processes.

Genetic testing. First-line is typically a targeted congenital-myopathy/nemaline-myopathy multigene panel (ACTA1, NEB, TPM2, TPM3, TNNT1, CFL2, KBTBD13, KLHL40, KLHL41, LMOD3, MYPN, MYO18B, ADSSL1) or exome/genome sequencing, given the genetic heterogeneity of NM; single-gene ACTA1 sequencing is reasonable when the clinical/histopathological picture (especially intranuclear rods or a severe congenital presentation) points specifically to ACTA1. Recessive cases require deliberate assessment of biallelic status (zygosity, potential compound heterozygosity), since dominant de novo missense is the default prior.

Imaging. Muscle MRI fatty-infiltration patterns are used adjunctively to help distinguish congenital myopathy subtypes, though no ACTA1-specific validated MRI signature was retrieved in this search.

Prenatal diagnosis. Ultrasound findings suggestive of the severe end of the spectrum include reduced fetal movement, multiple joint contractures/arthrogryposis, and polyhydramnios (typically apparent from ~28 weeks); genetic confirmation is by CVS/amniocentesis testing for a known familial variant, or by prenatal exome sequencing in undiagnosed severe fetal akinesia (search synthesis).

Differential diagnosis. Other congenital myopathies presenting with neonatal hypotonia must be distinguished, particularly: central core disease/multiminicore disease (RYR1) — important because of a different malignant hyperthermia risk profile (see §12); centronuclear/myotubular myopathy (MTM1, DNM2, BIN1); congenital muscular dystrophies; spinal muscular atrophy; congenital myasthenic syndromes; and the other nemaline-myopathy genes listed above.

11. Outcome/Prognosis

Mortality. In the landmark 143-patient cohort, 30 patients (~21%) died, the majority within the first 12 months of life, with all deaths attributable to respiratory insufficiency, which was "frequently underrecognized in older patients" (PMID:11558787). A more recent, severity-enriched pediatric systematic review (n=101) reported 36% mortality, with causes of death including sepsis, respiratory insufficiency, cardiopulmonary arrest, infection, or hypoxic-ischemic brain injury (PMC10032635) — the higher figure likely reflects a case-report-based sampling bias toward more severe/unusual presentations rather than a true increase in population mortality; both figures are reported here rather than reconciled, per the source cohorts' differing methodology.

Predictors of early mortality: arthrogryposis, neonatal respiratory failure, and failure to achieve early motor milestones (PMID:11558787).

Genotype-specific survival. In the largest cohort to date (n=275), survival differed by molecular diagnosis: NEB-NM patients had higher survival than patients with no molecular diagnosis, and ACTA1-NM patients required feeding tubes and invasive ventilation more often than NEB-NM patients in the first year of life (PMID:40661861).

Morbidity in survivors. Respiratory-tract-infection and feeding-difficulty morbidity characteristically diminish with age, while chronic weakness, progressive scoliosis, and joint contractures persist as the dominant drivers of long-term disability. "Aggressive early management is warranted in most cases of congenital nemaline myopathy" (PMID:11558787).

Functional outcome ranges widely by subtype — from ventilator-dependent, non-ambulatory survivors (severe/intermediate congenital forms) to independently ambulatory adults with mild residual weakness (typical congenital, childhood-, and adult-onset forms) — but no formal ACTA1-specific ambulation/PROMIS/EQ-5D outcome dataset was located.

12. Treatment

There is no approved disease-modifying or curative therapy; management is entirely supportive and multidisciplinary.

Respiratory: surveillance for nocturnal hypoventilation; noninvasive ventilation (BiPAP) is an important therapeutic option in patients with chronic respiratory failure, progressing to invasive ventilation/tracheostomy in the most severe cases (search synthesis; PMC6945071). NCIT: C15747 (Supportive Care).

Nutrition/feeding: nasogastric feeding in the neonatal period, frequently progressing to percutaneous gastrostomy; dysphagia rehabilitation/speech-language and oral-motor therapy has shown potential to improve swallowing function even in children with severe oral-motor dysfunction (search synthesis of case series). NCIT: C15433 (Nutritional Support).

Orthopedic/rehabilitative: physical and occupational therapy for contracture management and functional mobility (NCIT:C15302 Physical Therapy; NCIT:C15315 Rehabilitation); scoliosis surveillance with spinal fusion surgery when indicated (NCIT:C15329 Surgical Procedure), requiring specific anesthetic precautions — avoidance of succinylcholine and other depolarizing/triggering agents given the risk of anesthesia-induced rhabdomyolysis and life-threatening hyperkalemia in structural myopathies broadly; note that isolated ACTA1/nemaline myopathy is not itself considered malignant-hyperthermia-susceptible in the way RYR1-related core myopathies are, an important distinction for anesthetic risk-stratification (search synthesis of orphananesthesia/anesthesia-literature guidance).

Pharmacotherapy. No approved drug. L-tyrosine has been trialed empirically in small open-label case series (250–3000 mg/day, 2 months to 5 years) with subjectively reported short-term improvements in strength/energy, but "due to various limitations (no placebo group, large age variability, and variable disease mutations), no firm conclusions could be made as to efficacy" — and subsequent preclinical zebrafish and ACTA1(D286G) mouse studies found L-tyrosine treatment does NOT improve skeletal muscle performance, directly contradicting the earlier anecdotal reports (search synthesis; biorxiv preprint on L-tyrosine in zebrafish/mouse NM models). This is a useful illustration of a therapy that looked promising in case reports but failed a more rigorous preclinical test.

Investigational/gene-directed approaches (all preclinical): - Cardiac α-actin (ACTC1) over-expression therapy for dominant ACTA1 disease — leveraging the same rescue biology described in §2/§6 — has been directly tested as a therapeutic strategy in a mouse model of dominant ACTA1 disease (PMID:23736297, "Cardiac α-actin over-expression therapy in dominant ACTA1 disease"). - A "Knockdown-and-Replace" (KDAR) strategy — allele-nonspecific silencing of the mutant/dominant-negative ACTA1 transcript combined with replacement — is in early preclinical development (Rashnonejad et al., Foundation Building Strength-funded program), reflecting the field's recognition that simple gene-addition therapy cannot work against a dominant-negative poison-subunit mechanism (search synthesis; buildingstrength.org). - AAV-based gene-therapy programs for nemaline myopathy more broadly (Z-disc fragment expression, microRNA-mediated knockdown) have so far been directed at NEB and TNNT1, not ACTA1 specifically, and remain in early preclinical stages without demonstrated functional benefit to date (PMID:34561123, "Recent advances in nemaline myopathy," Neuromuscul Disord 2021). - No ACTA1-specific interventional clinical trial (with an NCT identifier) was identified in this search. Several natural history studies are actively recruiting or planned (UK: NCT06670378; Belgium: NCT07201636; Spain: NCT07488806), reflecting trial-readiness-building efforts rather than a therapeutic intervention.

Treatment outcomes/adverse events: no systematic pharmacovigilance (FAERS) data specific to ACTA1-directed therapy exist, since none is approved.

13. Prevention

Primary prevention is not possible for de novo dominant disease. For families with an identified dominant or recessive (carrier) pathogenic variant, genetic counseling regarding recurrence risk is the principal preventive intervention; empirical de novo recurrence-risk figures (generic, not ACTA1-specific) of ~1–5% (higher with documented parental mosaicism) should be communicated per standard genetic-counseling practice for de novo dominant conditions.

Secondary prevention/screening: prenatal diagnosis (CVS/amniocentesis) is available once a familial variant is known; preimplantation genetic testing (PGT-M) is an option for families with an identified pathogenic variant. Population/carrier screening is not standard, given that the great majority of pathogenic variants are private/de novo rather than population-recurrent; carrier screening would only be relevant in known recessive families or high-consanguinity settings.

Tertiary prevention: early, proactive multidisciplinary surveillance (respiratory function monitoring, nutritional assessment, scoliosis screening) is explicitly recommended to prevent secondary complications (aspiration pneumonia, malnutrition, progressive respiratory compromise from untreated scoliosis) — "aggressive early management is warranted in most cases" (PMID:11558787).

Immunization/public health/prophylaxis: no disease-specific measures beyond standard pediatric immunization (particularly respiratory pathogens, given the disproportionate respiratory mortality burden) were identified; this is inferred rather than explicitly sourced.

14. Other Species / Natural Disease

No well-documented, naturally occurring ACTA1-orthologous disease in companion animals, livestock, or wildlife was identified in this search (in contrast to some other neuromuscular genes with recognized veterinary counterparts) — this is flagged as a genuine data gap rather than an assumed absence, since OMIA was not directly queried in this session.

Orthologs: mouse Acta1 (MGI:87902, chromosome 8); zebrafish acta1a/acta1b (the predominant actin isoforms in fast myofibers). Cross-species conservation of the actin fold is extremely high (skeletal, cardiac, and smooth-muscle actin isoforms are >90% identical), which is itself mechanistically relevant (§2, §6) — cardiac α-actin can substitute functionally for skeletal α-actin in mouse skeletal muscle.

15. Model Organisms

Mouse models — the best-characterized animal system for ACTA1 disease: - KI.Acta1(H40Y) knock-in mouse: heterozygous mice recapitulate the severe human H40Y phenotype with high fidelity — premature lethality, severe muscle weakness, reduced mobility, nemaline rods, and muscle fiber atrophy — mirroring the human patient with this variant, who died at 2 months of age (search synthesis; PMC10548277). - Tg.ACTA1(D286G) transgenic mouse: overexpresses mutant protein to ~20% of total actin; produces only mild nemaline pathology with minimal behavioral weakness and a normal lifespan, in contrast to the corresponding human patient (who died at 9 months) — an explicit model-fidelity limitation: the transgenic overexpression approach under-recapitulates severity relative to the human disease, and the original report is titled as a "cautionary note on muscle transgene expression" for this reason (search synthesis; PMC3235150). - Both models have been characterized by in vivo MRI/³¹P-MRS, showing impaired muscle function and altered energy metabolism consistent with the bioenergetic mechanism in §6 (PMC3629063; PMC3748127). - Acta1-null (complete knockout) mice die by 9 days after birth — a very severe phenotype directly analogous to human recessive-null disease — and are rescuable to normal-lifespan survival with no gross skeletal-muscle pathology by transgenic overexpression of cardiac α-actin (ACTC1), providing the mechanistic basis for the compensation hypothesis discussed in §2/§6 (PMID:19468071).

Zebrafish models: transgenic lines expressing disease-linked dominant mutations (e.g., p.Val165Met) on the endogenous zebrafish acta1a fast-fiber actin transcript reproduce myopathic phenotypes — delayed hatching, curved body, reduced touch-evoked escape-response motility by 5 days post-fertilization — with severity correlating to the corresponding human mutation's severity; phalloidin staining confirms actin aggregates, and electron microscopy shows Z-line thickening and myofibrillar disorganization (search synthesis). This model was used to test — and refute — L-tyrosine efficacy (§12).

Cellular/iPSC models: ACTA1(H40Y) patient-derived iPSC-differentiated skeletal myocytes display mitochondrial defects, an independent line of evidence supporting the bioenergetic-failure branch of the mechanism (PMID:36796746); patient dermal fibroblasts (non-muscle cell type, used as an accessible surrogate) were used to dissect the full actin-polymerization → RhoA/ROCK → mitochondrial-dysfunction chain, including pharmacological reversal with linoleic acid/L-carnitine (PMC10740811).

Model limitations, generally: the D286G transgenic-overexpression mouse under-recapitulates human severity, cautioning against transgene-dosage artifacts; conversely, patient fibroblasts (used for the mitochondrial mechanism) are a non-muscle surrogate cell type, so extrapolation of the RhoA/ROCK/mitochondrial findings to differentiated skeletal myofibers in situ, while independently supported by iPSC-myocyte data, still carries residual translational uncertainty.

No Drosophila or C. elegans ACTA1-orthologous disease model was identified in this search — a data gap, though invertebrate actin structure-function work (e.g., on the unrelated Drosophila indirect-flight-muscle actin gene Act88F) exists as a general precedent for actin-mutation biomechanics rather than as a disease model of this gene.

Summary of Key Data Gaps (flagged rather than filled)

• No confirmed Orphanet ORPHA code for the ACTA1-specific NM subtype was retrieved (vs. the general nemaline myopathy entry).
• No ACTA1-specific germline-mosaicism recurrence-risk quantification exists; generic de novo figures were used as a proxy.
• No transcriptomic/proteomic/spatial-omics dataset on ACTA1 patient muscle was located.
• No formal quality-of-life instrument (EQ-5D/SF-36/PROMIS) data specific to this gene were found.
• No documented naturally occurring veterinary/companion-animal ACTA1 disease was found (absence not confirmed against OMIA directly in this session).
• No ACTA1-specific interventional (NCT) clinical trial was identified; only natural-history studies.

Sources

• OMIM #161800 — Congenital Myopathy 2A / OMIM *102610 — ACTA1
• Severe ACTA1-related nemaline myopathy: intranuclear rods, cytoplasmic bodies, and enlarged perinuclear space (PMC9271256)
• An Update on Reported Variants in the Skeletal Muscle α-Actin (ACTA1) Gene (PMC11918651)
• Actin Polymerization Defects Induce Mitochondrial Dysfunction in Cellular Models of Nemaline Myopathies (PMC10740811)
• ACTA1 H40Y mutant iPSC-derived skeletal myocytes — PMID:36796746
• Nemaline myopathy: a clinical study of 143 cases — PMID:11558787
• Pediatric Nemaline Myopathy: A Systematic Review Using Individual Patient Data (PMC10032635)
• Retrospective Cohort Analysis of 275 Patients With Nemaline Myopathy — PMID:40661861
• Skeletal muscle α-actin diseases (actinopathies): pathology and mechanisms — PMID:22825594
• The pathogenesis of ACTA1-related congenital fiber type disproportion — PMID:17387733
• Dysfunctional sarcomere contractility in ACTA1-related NEM3 — PMID:29328520
• Recessive ACTA1 variant causes congenital muscular dystrophy with rigid spine — PMID:25182138
• Rescue of skeletal muscle α-actin–null mice by cardiac (fetal) α-actin — PMID:19468071
• Cardiac α-actin over-expression therapy in dominant ACTA1 disease — PMID:23736297
• Evidence for a dominant-negative effect in ACTA1 nemaline myopathy — PMID:15198992
• Heterogeneity of nemaline myopathy cases with ACTA1 mutations — PMID:15236405
• Dilated cardiomyopathy-associated ACTA1 R256H mutation — PMID:38559046
• Recent advances in nemaline myopathy — PMID:34561123
• Different Mouse Models of Nemaline Myopathy Harboring Acta1 Mutations (PMC10548277)
• Actin Nemaline Myopathy Mouse Reproduces Disease... (PMC3235150)
• Nemaline Myopathy-Related ACTA1 D286G Prevents Proper Strong Myosin Binding (PMC3447773)
• Nemaline Myopathy — NORD
• ACTA1 gene — MedlinePlus
• ACTA1 gene assignment to chromosome 1q42.13 — PMID:10072583

Reference Validation

Checked with linkml-reference-validator 0.3.0rc3.

Quotes not found in the cited source

Searched the abstract, any retrieved full text, and the title. A quote drawn from a part of the paper that was not retrieved will appear here too, so check before treating one as invented:

Every one of these was searched against an abstract alone, with no full text retrieved - marked abstract only below. Where full text can be fetched, re-running with it will settle them; where the source publishes only a summary to PubMed, as GeneReviews chapters do, it will not, and the quote has to be checked by hand against the chapter itself.

• PMC:PMC3447773 (abstract only): "prevents proper strong myosin binding and triggers muscle weakness"
• closest text in source: "This phenomenon is likely to prevent proper myosin cross-bridge binding, limiting the fraction of actomyosin interactions in the strong binding state"
• PMID:15236405 (abstract only): "the marked variability in clinical phenotype among patients with different mutations in ACTA1 suggested that both the site of the mutation and the nature of the amino acid change have differential effects on thin-filament formation and protein-protein interactions"
• closest text in source: "The skeletal muscle alpha-actin gene (ACTA1) is one of five genes for thin filament proteins identified so far as responsible for different forms of NM"

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

• HP:0001319 (1 mention) - the report calls it "Near-universal in congenital forms"; HP calls it Neonatal hypotonia
• HP:0003324 (1 mention) - the report calls it "Defining feature of "typical" form"; HP calls it Generalized muscle weakness
• HP:0001265 (1 mention) - the report calls it "Common"; HP calls it Hyporeflexia
• HP:0003701 (1 mention) - the report calls it "68% (pediatric systematic review, n=101, PMC10032635)"; HP calls it Proximal muscle weakness

Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a related synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

• HP:0002705 (1 mention) - the report calls it "High-arched palate"; HP calls it High, narrow palate, and lists "Narrow, high-arched palate" among its other names
• HP:0002650 (1 mention) - the report calls it "Kyphoscoliosis/scoliosis"; HP calls it Scoliosis
• HP:0001989 (1 mention) - the report calls it "Fetal akinesia/reduced fetal movement"; HP calls it Fetal akinesia sequence
• CL:0000188 (1 mention) - the report calls it "Skeletal muscle fiber"; CL calls it cell of skeletal muscle, and lists "skeletal muscle cell" among its other names

Prefixes with no resolver

Terms carrying these prefixes were not checked either way, because no configured ontology covers them. An unrecognised prefix may name an ontology this run could not reach as easily as one that does not exist, so nothing here is evidence of fabrication: MGI.